The Technical Analyst
Intec Pharma Ltd [NTEC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Intec Pharma Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-12.45% $9.63
America/New_York / 31 des 1970 @ 19:00
| RATING 2021-08-09 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/19 | 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.29 - 9.98 ( +/- 3.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-07-23 | Hayes William B | Sell | 250 | Stock Option (right to buy) |
| 2021-07-23 | Hayes William B | Sell | 250 | Stock Option (right to buy) |
| 2021-07-23 | Hayes William B | Sell | 500 | Stock Option (right to buy) |
| 2021-07-23 | Karah Hila | Sell | 281 | Stock Option (right to buy) |
| 2021-07-23 | Karah Hila | Sell | 250 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 59 transactions |
| Buy: 3 599 185 | Sell: 7 817 315 |
Forecast:
01:40 - $4.89
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.63 (-12.45% ) |
| Volume | 0.988 mill |
| Avg. Vol. | 1.051 mill |
| % of Avg. Vol | 94.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NTEC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NTEC
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
Latest Press Releases
2021-08-03 12:45:00 - Press Release
Intec Announces Expected Closing Date Of Decoy Merger
Jerusalem, aug. 3, 2021 /prnewswire/ -- intec parent, inc. (nasdaq: ntec) ("intec parent" or the "company"), today announced that the pending and previously announced reverse merger (the "decoy merger") with decoy biosystems, inc. ("decoy") is currently expected to close after market hours today, tuesday, august 3, 2021, subject to satisfaction or waiver of all closing conditions. immediately following the closing, the combined company will be renamed "indaptus therapeutics, inc.", and is expected to begin trading on the nasdaq capital market under the new ticker symbol "indp" upon the commencement of trading on wednesday, august 4, 2021.
2021-03-26 23:02:00 - Press Release
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Intec Pharma Ltd. - Ntec
New york, march 26, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018 and 2019 iss securities class action services report and headquartered at the empire state building in new york city, is investigating intec pharma ltd. ("ntec" or the "company") (ntec) relating to its proposed merger with decoy biosystems.
2021-03-22 20:16:00 - Press Release
Shareholder Alert: Weisslaw Llp Investigates Intec Pharma Ltd.
New york, march 22, 2021 /prnewswire/ -- weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of intec pharma ltd. ("intec" or the "company") (nasdaq: ntec) in connection with the proposed acquisition of the company by decoy biosystems, inc.("decoy").
2021-03-17 13:47:00 - Press Release
Intec Pharma Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Intec Pharma Ltd. - Ntec
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of intec pharma ltd. (“the company”) (nasdaqcm: ntec) to decoy biosystems, inc. pursuant to which intec shareholders are expected to only own approximately 25% of the combined company, on a fully diluted basis. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the company. if you believe that this transaction undervalues the company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call ksf managing partner lewis s...
2021-03-16 20:18:00 - Press Release
Intec Pharma Announces Filing Of 2020 Annual Report On Form 10-k
Jerusalem , march 16, 2021 (globe newswire) -- intec pharma ltd. (nasdaq: ntec) (“intec” or “the company”) today announces that it has filed its annual report on form 10-k for the year ended december 31, 2020 with the u.s. securities and exchange commission. a copy of the annual report is available on intec's website, www.intecpharma.com, by selecting “investors” and then “financials” and “sec filings”.
Latest News
2021-08-03 12:45:00 - PRNewsWire
Intec Announces Expected Closing Date of Decoy Merger
JERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ: NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with Decoy Biosystems, Inc. ("Decoy") is currently expected to close after market hours today, Tuesday, August 3, 2021, subject to satisfaction or waiver of all closing conditions. Immediately following the closing, the combined company will be renamed "Indaptus Therapeutics, Inc.", and is expected to begin trading on The Nasdaq Capital Market under the new ticker symbol "INDP" upon the commencement of trading on Wednesday, August 4, 2021.
2021-07-29 17:34:27 - InvestorPlace
NTEC Stock: 10 Things to Know About Red-Hot Intec Pharma
NTEC stock is riding high today without any news. It seems investors are getting hyped up ahead of its merger with Decoy Biosystems.
2021-07-29 13:11:28 - PennyStocks
3 Biotech Penny Stocks To Watch On Robinhood IPO Day
These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO The post 3 Biotech Penny Stocks To Watch On Robinhood IPO Day appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-07-22 17:06:54 - PennyStocks
Hot Penny Stocks to Buy Now? 4 You Need to Know About
These hot penny stocks may deserve a place on your watchlist this month The post Hot Penny Stocks to Buy Now? 4 You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-07-13 15:25:29 - PennyStocks
Best Penny Stocks To Buy Before Marijuana Legalization? 4 To Watch Now
Marijuana legalization is a hot topic & some penny stocks are benefiting in 2021. The post Best Penny Stocks To Buy Before Marijuana Legalization?
2021-06-22 16:24:09 - PennyStocks
Top 10 Biotech Penny Stocks to Watch in July 2021
Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-06-20 13:09:25 - PennyStocks
Best Penny Stocks To Buy Now? 7 To Watch This Week
2021-04-01 14:33:53 - Schaeffers Research
The Week Where New York Legalizes Recreational Marijuana
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.
2021-03-26 23:02:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intec Pharma Ltd. - NTEC
NEW YORK, March 26, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Intec Pharma Ltd. ("NTEC" or the "Company") (NTEC) relating to its proposed merger with Decoy Biosystems.
2021-03-22 20:16:00 - PRNewsWire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intec Pharma Ltd.
NEW YORK, March 22, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intec Pharma Ltd. ("Intec" or the "Company") (NASDAQ: NTEC) in connection with the proposed acquisition of the Company by Decoy Biosystems, Inc.("Decoy").